1. Stopping GLP-1 receptor agonists linked to higher cardiovascular and mortality risk in type 2 diabetes

A retrospective cohort study in The Lancet Regional Health – Europe followed 80,302 people with type 2 diabetes and no prior cardiovascular disease who started a GLP-1 receptor agonist at 301 Italian diabetes clinics between 2004 and 2024; 60.5% later stopped treatment. After propensity score matching (28,713 per group), discontinuation was associated with about twice the rate of myocardial infarction, stroke or death (HR 2.03, 95% CI 1.92–2.14) and a much higher rate of all-cause death (HR 4.81), with a stronger association in people with obesity. The authors stress that causality cannot be inferred: reasons for stopping were not recorded and reverse causation is likely to explain part of the mortality signal. For safety teams, the study is a reminder that discontinuation, often driven by gastrointestinal intolerance, is itself part of the benefit-risk picture, and that observational discontinuation analyses need careful handling of confounding before they inform labelling or risk communication. The Lancet Regional Health – Europe, 9 Nov 2026

2. Long-term inhaled mometasone worsens a severity marker in sickle cell disease without asthma

A single-centre phase 2 randomised trial in JAMA Network Open gave 77 adults with sickle cell disease and episodic cough or wheeze, but no asthma diagnosis, once-daily inhaled mometasone or placebo for 48 weeks. Soluble VCAM-1, a marker of disease severity, rose by 42% with mometasone relative to placebo; emergency visits, hospital admissions and acute chest syndrome (8 episodes in 5 patients versus 4 in 3) were numerically higher with mometasone, though not statistically significant. The authors advise against long-term inhaled mometasone in this population without a definitive asthma diagnosis. The finding is relevant to off-label use monitoring: a treatment that looked beneficial in a short trial showed a possible harm signal with longer exposure. JAMA Network Open, 10 Nov 2026

3. PepGen reports new myotonic dystrophy data while its US partial clinical hold continues

PepGen published interim results from the second cohort (10 mg/kg) of its Phase 2 FREEDOM2 study of PGN-EDODM1 in myotonic dystrophy type 1. The company reports that all treatment-related adverse reactions were mild or moderate, nausea was most common, temporary increases in urinary protein were seen after the first dose, and four mild kidney-related adverse events occurred. The study has been under an FDA partial clinical hold since March 2026 over a nonclinical finding in mice, so it continues only outside the US (Canada, the UK, South Korea, Australia and New Zealand) while further mouse studies are run. The case shows how a nonclinical hold can shift early clinical safety data generation entirely ex-US, and why renal monitoring data from those sites will matter for the response to FDA. PepGen community letter, 10 Nov 2026

4. EMA and HMA publish agenda for the second forum on EudraVigilance and signal detection

EMA has updated the agenda for the second HMA/EMA multi-stakeholder forum on EudraVigilance and signal detection, to be held online on 1 December 2026 to mark 25 years of EudraVigilance. The stated objectives are to inform stakeholders about ongoing and forthcoming developments in international guidance, signal management and the use of real-world evidence, and to strengthen collaboration. EU signal management and EudraVigilance teams may find it a useful preview of upcoming changes to signal processes. EMA event page, updated 10 Nov 2026


This news brief is for information only and is not medical or regulatory advice. Source links open the original publication in a new tab.

Follow Safety Strategy on LinkedIn (opens in a new tab) for updates. All news briefs · News and articles